Contents:

1 Executive Summary 2 About Cancer Highlights 3 Methodologies 4 Table of Contents 4.1 List of Figures 4.2 List of Tables 5 Introduction 5.1 The Scope of this Report 5.2 Definitions 5.3 Abbreviations 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 6.1.1 Carboxy-lyase Activity Targets 6.1.2 Catalytic Activity Targets 6.1.3 Cell Adhesion Molecule Activity Targets 6.1.4 Chaperone Activity Targets 6.1.5 Cysteine-Type Peptidase Activity Targets 6.1.6 Cytokine Activity Targets 6.1.7 DNA Binding Targets 6.1.8 DNA Repair Protein Targets 6.1.9 DNA Topoisomerase Activity Targets 6.1.10 DNA-Directed DNA Polymerase Activity Targets 6.1.11 Glutathione Transferase Activity Targets 6.1.12 G-Protein Coupled Receptor Activity Targets 6.1.13 Growth Factor Activity Targets 6.1.14 Hormone Activity Targets 6.1.15 Hydrolase Activity Targets 6.1.16 Kinase Activity Targets 6.1.17 Kinase Regulator Activity Targets 6.1.18 Ligand-Dependent Nuclear Receptor Activity Targets 6.1.19 Ligase Activity Targets 6.1.20 Lipid Kinase Activity Targets 6.1.21 Lipid Phosphatase Activity Targets 6.1.22 MHC Class I Receptor Activity Targets 6.1.23 Molecular Function Unknown Targets 6.1.24 Motor Activity Targets 6.1.25 Oxidoreductase Activity Targets 6.1.26 Phosphorylase Activity Targets 6.1.27 Protein Binding Targets 6.1.28 Protein Serine/Threonine Kinase Activity Targets 6.1.29 Protein Tyrosine Phosphatase Activity Targets 6.1.30 Protein-Tyrosine Kinase Activity Targets 6.1.31 Receptor Activity Targets 6.1.32 Receptor Binding Targets 6.1.33 Receptor Signaling Complex Scaffold Activity Targets 6.1.34 RNA Binding Targets 6.1.35 Serine-Type Peptidase Activity Targets 6.1.36 Structural Constituent Of Cytoskeleton Targets 6.1.37 Superoxide Dismutase Activity Targets 6.1.38 T Cell Receptor Activity Targets 6.1.39 Transcription Factor Activity Targets 6.1.40 Transcription Regulator Activity Targets 6.1.41 Translation Regulator Activity Targets 6.1.42 Transmembrane Receptor Activity Targets 6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 6.1.44 Transporter Activity Targets 6.1.45 Other Targets 6.2 The Cancer Genome Project and Lymphoma Targets 6.2.1 Lymphoma Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 6.3 Structure-based Drug Design in Lymphoma is Stimulated by Available Structure Data on Biological Targets 6.4 Target-Target Interactions among Identified Lymphoma Targets 6.5 The Drug-Target Interactome 6.6 Protein Expression Levels of Identified Drug Targets of Lymphoma Drugs 6.7 Pathway Analysis of Lymphoma Drug Targets 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline? 7.1 Terminated Drug Target Profiles in Lymphoma 7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lymphoma Pipeline 7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline 7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lymphoma Pipeline 7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline 7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lymphoma Pipeline 7.7 Development Profiles of All Lymphoma Drug Target Profiles 8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound 8.1 Small Molecules 8.1.1 Background 8.1.2 Targets in Lymphoma 8.2 Peptide/Protein Drugs 8.2.1 Background 8.2.2 Targets in Lymphoma 8.3 Antibodies and Antibody-like Structures 8.3.1 Background 8.3.2 Targets in Lymphoma 8.4 Nucleic Acid Therapies 8.4.1 Background 8.4.2 Targets in Lymphoma 8.5 Gene Therapy 8.5.1 Background 8.5.2 Targets in Lymphoma 8.6 The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma 8.7 Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets 9 Selecting a Sub-Indication of Lymphoma for Drug Development 9.1 B-cell Lymphoma 9.1.1 Players and their Compared Pipeline 9.1.2 Where is the Real Competition? 9.1.3 How Successful are They in Their Targeting Strategy? 9.2 Hodgkin’s Lymphoma 9.2.1 Players and their Compared Pipeline 9.2.2 Where is the Real Competition? 9.2.3 How Successful are They in Their Targeting Strategy? 9.3 Lymphoma (general) 9.3.1 Players and their Compared Pipeline 9.3.2 Where is the Real Competition? 9.3.3 How Successful are They in Their Targeting Strategy? 9.4 Non-Hodgkin’s Lymphoma 9.4.1 Players and their Compared Pipeline 9.4.2 Where is the Real Competition? 9.4.3 How Successful are They in Their Targeting Strategy? 9.5 T-cell Lymphoma 9.5.1 Players and their Compared Pipeline 9.5.2 Where is the Real Competition? 9.5.3 How Successful are They in Their Targeting Strategy? 10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator 10.1 Abbott 10.2 Abiogen 10.3 AEgera 10.4 Aeterna Zentaris 10.5 Affimed Therapeutics 10.6 Aida Pharmaceuticals 10.7 Alfa Wassermann 10.8 Alfacell 10.9 Allos Therapeutics 10.10 Amgen 10.11 Anadys Pharmaceuticals 10.12 Antigenics 10.13 Archer Biosciences 10.14 Ariad 10.15 Ascenta Therapeutics 10.16 Astellas 10.17 AstraZeneca 10.18 Attenuon 10.19 AVEO 10.20 Benitec 10.21 BioCryst Pharmaceuticals 10.22 Biogen Idec 10.23 Biolex 10.24 Boehringer Ingelheim 10.25 Borean Pharma 10.26 Bristol-Myers Squibb 10.27 BTG 10.28 Calistoga Pharmaceuticals 10.29 Cell Therapeutics 10.30 Cephalon 10.31 Cyclacel 10.32 Cylene Pharmaceuticals 10.33 Cytokinetics 10.34 Daiichi Sankyo 10.35 Dainippon Sumitomo Pharma 10.36 Dara Biosciences 10.37 Dynavax Technologies 10.38 Eisai 10.39 Eli Lilly 10.40 Enzon 10.41 EpiCept 10.42 Exelixis 10.43 Favrille 10.44 Gemin X Pharmaceuticals 10.45 Genentech 10.46 Genmab 10.47 GenPat77 10.48 Genta 10.49 Genzyme 10.50 GlaxoSmithKline 10.51 Gloucester Pharmaceuticals 10.52 Hayashibara 10.53 Hoffmann-La Roche 10.54 Human Genome Sciences 10.55 Hy BioPharma 10.56 ImClone Systems 10.57 Immunomedics 10.58 Inex 10.59 Innate Pharma 10.60 InNexus Biotechnology 10.61 Intracel 10.62 Italfarmaco 10.63 Johnson & Johnson 10.64 Kissei 10.65 Kyowa Hakko Kirin 10.66 Ligand 10.67 Lorus Therapeutics 10.68 MacroGenics 10.69 Meda 10.70 Medarex 10.71 MedImmune 10.72 MethylGene 10.73 Micromet 10.74 Nektar Therapeutics 10.75 National Institute of Health (USA) 10.76 Novartis 10.77 Oncothyreon 10.78 Pfizer 10.79 Pharmacyclics 10.80 PharmaMar 10.81 ProNAi Therapeutics 10.82 Reata Pharmaceuticals 10.83 Rigel 10.84 Sanofi-Aventis 10.85 Santaris Pharma 10.86 SBIO 10.87 Seattle Genetics 10.88 Shire 10.89 SuperGen 10.90 Takeda 10.91 Telik 10.92 Titan Pharmaceuticals 10.93 TopoTarget 10.94 Transgene 10.95 Trubion 10.96 Vaccinex 10.97 Vertex Pharmaceuticals 10.98 VGX Pharmaceuticals 10.99 Vion Pharmaceuticals 10.100 VioQuest 10.101 Wyeth 10.102 Xencor 10.103 Yakult Honsha 10.104 Zenyaku Kogyo 10.105 ZymoGenetics 10.106 Non-industrial Source 11 Disclaimer 12 Drug Index 13 Company Index 4.1 List of Figures Figure 1: Overall Breakdown of the Included Lymphoma Therapeutic Pipeline by Sub-Indication and Stage of Development Figure 2: Visualization of Target-Target Interactions Among Lymphoma Drug Targets Figure 3: The Drug-Protein Interactome of Lymphoma Drugs –Clusters I Figure 4: The Drug-Protein Interactome of Lymphoma Drugs – Clusters II Figure 5: Head-to-Head Targeting Interactome of Lymphoma Drugs Figure 6: Distribution of Compound Types among Lymphoma Drugs Figure 7: Primary Sub-cellular Localization of Drug Targets Figure 8: Breakdown of the B-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 9: Breakdown of the B-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development Figure 10: Breakdown of the Hodgkin’s Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 11: Breakdown of the Hodgkin’s Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development Figure 12: Breakdown of the Lymphoma (general) Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 13: Breakdown of the Lymphoma (general) Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development Figure 14: Breakdown of the Non-Hodgkin’s Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 15: Breakdown of the Non-Hodgkin’s Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development Figure 16: Breakdown of the T-cell Lymphoma Pipeline (I) - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 17: Breakdown of the T-cell Lymphoma Pipeline (II) - Displaying the Number of Drugs by Compound Strategy and Stage of Development 4.2 List of Tables Table 1: Competitive Pressure Force Among Lymphoma Drugs Table 2: Overview of Drug Target Profile Themes Table 3: Drug Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census Table 4: Identity of Lymphoma Drug Targets with Available Biological Structures Table 5: Number of Target-Target Interactions among Lymphoma Drug Targets Table 6: Drug-Protein Interactome Clusters Table 7: Lymphoma Drug Targets with Available Protein Expression Profiles Table 8: Pathway Summary Table 9: Drug Targets without any Identified Assigned Pathways Table 10: Pathway Profile According to BioCarta of Lymphoma Drug Targets Table 11: Pathway Profile According to KEGG of Lymphoma Drug Targets Table 12: Pathway Profile According to NetPath of Lymphoma Drug Targets Table 13: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness Table 14: Top Competitive Lymphoma Target Profiles Table 15: Terminated Drug Target Profiles in Lymphoma Table 16 New and Unique Lymphoma Targets in Pre-Registration to Marketed Table 17: New and Unique Lymphoma Targets in Phase III Clinical Development Table 18: New and Unique Lymphoma Targets in Phase II Clinical Development Table 19: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs Table 20 New and Unique Lymphoma Targets in Phase I Clinical Development Table 21: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs Table 22: New and Unique Lymphoma Targets in Preclinical Development Table 23: The Progression, Maturity and Competitive Comparison of Lymphoma Drug Target Profiles in Development Table 24: Overview of Compound Strategy Competition in Lymphoma Table 25:Overview of the Competitive Landscape of Small Molecular Drugs in Lymhpoma Table 26: Head-to-head Target Competing Small Molecule Drugs for the Treatment of Lymphoma Table 27: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Lymphoma Table 28: The Progression, Maturity and Competitive Comparison of Small Molecule Lymphoma Drug Target Profiles in Development Table 29: The Progression, Maturity and Competitive Comparison of Peptide Based Lymphoma Drug Target Profiles in Development Table 30:Overview of the Competitive Landscape of Protein Based Drugs in Lymhpoma Table 31: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in Lymphoma Table 32: The Progression, Maturity and Competitive Comparison of Protein Based Lymphoma Drug Target Profiles in Development Table 33:Overview of the Competitive Landscape of Antibody Drugs in Lymhpoma Table 34: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lymphoma Table 35: The Progression, Maturity and Competitive Comparison of AntibodyLymphoma Drug Target Profiles in Development Table 36:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lymhpoma Table 37: The Progression, Maturity and Competitive Comparison of Nucleic Acid Lymphoma Drug Target Profiles in Development Table 38: Vectors in Gene Therapy Table 39: The Progression, Maturity and Competitive Comparison of Gene Therapy Lymphoma Drug Target Profiles in Development Table 40: The Competition Through Close Mechanistic Approximation Among Drugs in Lymphoma Table 41: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets Table 42: Competitive Summary of Lymhpoma Drugs by Sub-Indication Table 43: Players in the Field of B-cell Lymphoma Drug Development and their Compared Pipeline Table 44: The Competition Through Close Mechanistic Approximation Between B-cell Lymphoma Drugs Table 45: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in B-cell Lymphoma Drug Development Table 46: Players in the Field of Hodgkin’s Lymphoma Drug Development and their Compared Pipeline Table 47: The Competition Through Close Mechanistic Approximation Between Hodgkin’s Lymphoma Drugs Table 48: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Hodgkin’s Lymphoma Drug Development Table 49: Players in the Field of Lymphoma (general) Drug Development and their Compared Pipeline Table 50: The Competition Through Close Mechanistic Approximation Between Lymphoma (general) Drugs . Table 51: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lymphoma (general)Drug Development Table 52: A) Investigators with Multiple Non-Hodgkin’s Lymphoma Drugs in Development B) Investigators with Ceased, Discontinued or Suspended Drugs Table 53: Players in the Field of Non-Hodgkin’s Lymphoma Drug Development and their Compared Pipeline Table 54: The Competition Through Close Mechanistic Approximation Between Non-Hodgkin’s Lymphoma Drugs Table 55: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Hodgkin’s Lymphoma Drug Development Table 56: Players in the Field of T-cell Lymphoma Drug Development and their Compared Pipeline Table 57: The Competition Through Close Mechanistic Approximation Between T-cell Lymphoma Drugs Table 58: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in T-cell Lymphoma Drug Development Table 59: Abbott's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 60: Abiogen's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 61: AEgera's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 62: Aeterna Zentaris’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 63: Affimed Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 64: Aida Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 65: Alfa Wassermann's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 66: Alfacell's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 67: Allos Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 68: Amgen's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 69: Anadys Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 70: Antigenics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 71: Archer Biosciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 72: Ariad's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 73: Ascenta Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 74: Astellas’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 75: AstraZeneca's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 76: Attenuon's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 77: AVEO's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 78: Benitec's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 79: BioCryst Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 80: Biogen Idec's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 81: Biolex's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 82: Boehringer Ingelheim's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 83: Borean Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 84: Bristol-Myers Squibb's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 85: BTG's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 86: Calistoga Pharmaceuticals' Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 87: Cell Therapeutics' Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 88: Cephalon's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 89: Cyclacel's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 90: Cylene Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 91: Cytokinetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 92: Daiichi Sankyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 93: Dainippon Sumitomo Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 94: Dara Biosciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 95: Dynavax Technologies’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 96: Eisai's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 97: Eli Lilly's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 98: Enzon's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 99: EpiCept's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 100: Exelixis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 101: Favrille's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 102: Gemin X Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 103: Genentech's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 104: Genmab's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 105: GenPat77's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 106: Genta's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 107: Genzyme's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 108: GlaxoSmithKline's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 109: Gloucester Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 110: Hayashibara's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 111: Hoffmann-La Roche's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 112: Human Genome Sciences’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 113: Hy BioPharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 114: ImClone Systems’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 115: Immunomedics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 116: Inex's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 117: Innate Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 118: InNexus Biotechnology's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 119: Intracel's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 120: Italfarmaco's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 121: Johnson & Johnson's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 122: Kissei's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 123: Kyowa Hakko Kirin's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 124: Ligand's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 125: Lorus Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 126: MacroGenics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 127: Meda's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 128: Medarex's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 129: MedImmune's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 130: MethylGene's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 131: Micromet's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 132: Nektar Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 133: National Institute of Health (USA)'s Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 134: Novartis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 135: Oncothyreon's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 136: Pfizer's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 137: Pharmacyclics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 138: PharmaMar's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 139: ProNAi Therapeutics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 140: Reata Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 141: Rigel's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 142: Sanofi-Aventis’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 143: Santaris Pharma's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 144: SBIO's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 145: Seattle Genetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 146: Shire's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 147: SuperGen's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 148: Takeda's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 149: Telik's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 150: Titan Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 151: TopoTarget's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 152: Transgene's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 153: Trubion's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 154: Vaccinex's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 155: Vertex Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 156: VGX Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 157: Vion Pharmaceuticals’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 158: VioQuest's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 159: Wyeth's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 160: Xencor's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 161: Yakult Honsha's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 162: Zenyaku Kogyo's Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 163: ZymoGenetics’ Included Lymphoma Pipeline Composition and Competitive Fall-Out Table 164: Non-industrial source's Included Lymphoma Pipeline Composition and Competitive Fall-Out

Companies Mentioned

- Abbott - Abiogen - AEgera - Aeterna Zentaris - Affimed Therapeutics - Aida Pharmaceuticals - Alfa Wassermann - Alfacell - Allos Therapeutics - Amgen - Anadys Pharmaceuticals - Antigenics - Archer Biosciences - Ariad - Ascenta Therapeutics - Astellas - AstraZeneca - Attenuon - AVEO - Benitec - BioCryst Pharmaceuticals - Biogen Idec - Biolex - Boehringer Ingelheim - Borean Pharma - Bristol-Myers Squibb - BTG - Calistoga Pharmaceuticals - Cell Therapeutics - Cephalon - Cyclacel - Cylene Pharmaceuticals - Cytokinetics - Daiichi Sankyo - Dainippon Sumitomo Pharma - Dara Biosciences - Dynavax Technologies - Eisai - Eli Lilly - Enzon - EpiCept - Exelixis - Favrille - Gemin X Pharmaceuticals - Genentech - Genmab - GenPat - Genta - Genzyme - GlaxoSmithKline - Gloucester Pharmaceuticals - Hayashibara - Hoffmann-La Roche - Human Genome Sciences - Hy BioPharma - ImClone Systems - Immunomedics - Inex - Innate Pharma - InNexus Biotechnology - Intracel - Italfarmaco - Johnson & Johnson - Kissei - Kyowa Hakko Kirin - Ligand - Lorus Therapeutics - MacroGenics - Meda - Medarex - MedImmune - MethylGene - Micromet - Nektar Therapeutics - National Institute of Health (USA) - Novartis - Oncothyreon - Pfizer - Pharmacyclics - PharmaMar - ProNAi Therapeutics - Reata Pharmaceuticals - Rigel - Sanofi-Aventis - Santaris Pharma - SBIO - Seattle Genetics - Shire - SuperGen - Takeda - Telik - Titan Pharmaceuticals - TopoTarget - Transgene - Trubion - Vaccinex - Vertex Pharmaceuticals - VGX Pharmaceuticals - Vion Pharmaceuticals - VioQuest - Wyeth - Xencor - Yakult Honsha - Zenyaku Kogyo - ZymoGenetics - Non-industrial Source